BrosMed Medical

The company's business model revolves around providing comprehensive solutions, from initial design and development to manufacturing and global distribution. BrosMed engages in both direct sales and OEM/ODM partnerships, leveraging its extensive manufacturing capacity—over 3 million balloon catheters annually—and a robust supply chain. This vertically integrated approach allows the firm to manage quality and costs effectively. The company's revenue is generated through the sale of its wide range of medical devices across more than 100 countries. A significant milestone was achieved on July 27, 2020, when BrosMed secured an undisclosed amount in a Series C funding round led by Hillhouse, with participation from other investors like Cathay Capital and Cowin Capital.

BrosMed's product portfolio is extensive, covering cardiovascular intervention, peripheral intervention, and neurovascular intervention. Key products include a variety of balloon dilatation catheters such as the Artimes Semi-Compliance and Apollo High-Pressure coronary catheters, the Conger Hydrophilic Guidewire, and the FreePath Catheter Sheath Introducer. The company also offers accessories like inflation devices, Y connector sets, and manifolds. A notable product is the RevoEdge High-Pressure Coronary Cutting Balloon, which has received the CE mark under the European Medical Device Regulation (MDR). BrosMed maintains compliance with global regulatory standards, including ISO 13485, QSR820, and cGMP, ensuring its products meet international safety and efficacy requirements.